Quince Therapeutics, Inc. financial data

Symbol
QNCX on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 294% % -61%
Debt-to-equity 629% % 368%
Return On Equity -370% % -337%
Return On Assets -51% % -40%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 55,681,490 shares 27%
Common Stock, Shares, Outstanding 54,494,965 shares 26%
Entity Public Float $23,200,000 USD -54%
Common Stock, Value, Issued $54,000 USD 26%
Weighted Average Number of Shares Outstanding, Basic 53,951,371 shares 25%
Weighted Average Number of Shares Outstanding, Diluted 53,951,371 shares 25%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $28,606,000 USD 77%
General and Administrative Expense $15,696,000 USD -14%
Operating Income (Loss) $50,727,000 USD 8.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $14,983,000 USD -35%
Income Tax Expense (Benefit) $75,000 USD -43%
Net Income (Loss) Attributable to Parent $56,979,000 USD -7%
Earnings Per Share, Basic -1 USD/shares 2.4%
Earnings Per Share, Diluted -1 USD/shares 2.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $6,452,000 USD
Cash, Cash Equivalents, and Short-term Investments $26,300,000 USD -45%
Other Assets, Current $96,000 USD 75%
Assets, Current $29,202,000 USD -44%
Property, Plant and Equipment, Net $616,000 USD 196%
Operating Lease, Right-of-Use Asset $481,000 USD -14%
Intangible Assets, Net (Excluding Goodwill) $67,726,000 USD 5%
Goodwill $0 USD
Other Assets, Noncurrent $11,874,000 USD 25%
Assets $109,899,000 USD -13%
Accounts Payable, Current $3,403,000 USD 110%
Accrued Liabilities, Current $5,121,000 USD 35%
Liabilities, Current $26,044,000 USD 380%
Deferred Income Tax Liabilities, Net $5,593,000 USD 3.9%
Operating Lease, Liability, Noncurrent $359,000 USD -20%
Other Liabilities, Noncurrent $778,000 USD 21%
Liabilities $108,840,000 USD 33%
Accumulated Other Comprehensive Income (Loss), Net of Tax $6,293,000 USD 84%
Retained Earnings (Accumulated Deficit) $420,993,000 USD -16%
Stockholders' Equity Attributable to Parent $1,059,000 USD -98%
Liabilities and Equity $109,899,000 USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,601,000 USD -15%
Net Cash Provided by (Used in) Financing Activities $87,000 USD -54%
Net Cash Provided by (Used in) Investing Activities $10,898,000 USD 22%
Common Stock, Shares Authorized 250,000,000 shares 150%
Common Stock, Shares, Issued 54,494,965 shares 26%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $1,559,000 USD 47%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6,452,000 USD 141%
Interest Paid, Excluding Capitalized Interest, Operating Activities $53,000 USD
Deferred Tax Assets, Valuation Allowance $91,488,000 USD 7.5%
Deferred Tax Assets, Gross $103,164,000 USD 5.9%
Operating Lease, Liability $473,000 USD -14%
Payments to Acquire Property, Plant, and Equipment $148,000 USD 279%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $54,105,000 USD -7.4%
Lessee, Operating Lease, Liability, to be Paid $558,000 USD -15%
Operating Lease, Liability, Current $114,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Two $142,000 USD 4.4%
Lessee, Operating Lease, Liability, to be Paid, Year One $149,000 USD 6.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $85,000 USD -18%
Lessee, Operating Lease, Liability, to be Paid, Year Three $128,000 USD -1.5%
Deferred Tax Assets, Operating Loss Carryforwards $87,188,000 USD 6.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $4,430,000 USD 2.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four $101,000 USD -53%
Additional Paid in Capital $415,705,000 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $11,676,000 USD -5.1%
Share-based Payment Arrangement, Expense $5,039,000 USD -15%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%